Gelderblom HJ - Search Results

1

Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans.

Loos WJ, Verweij J, Gelderblom HJ, de Jonge MJ, Brouwer E, Dallaire BK, Sparreboom A. Loos WJ, et al. Among authors: gelderblom hj. Anticancer Drugs. 1999 Sep;10(8):705-10. doi: 10.1097/00001813-199909000-00003. Anticancer Drugs. 1999. PMID: 10573202 Clinical Trial.

2

Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.

Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G, Verweij J. Sparreboom A, et al. Cancer Res. 1999 Apr 1;59(7):1454-7. Cancer Res. 1999. PMID: 10197613

3

Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function.

Gelderblom H, Verweij J, Brouwer E, Pillay M, de Bruijn P, Nooter K, Stoter G, Sparreboom A. Gelderblom H, et al. Drug Metab Dispos. 1999 Nov;27(11):1300-5. Drug Metab Dispos. 1999. PMID: 10534315

4

Topotecan lacks third space sequestration.

Gelderblom H, Loos WJ, Verweij J, de Jonge MJ, Sparreboom A. Gelderblom H, et al. Clin Cancer Res. 2000 Apr;6(4):1288-92. Clin Cancer Res. 2000. PMID: 10778953 Clinical Trial.

5

Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects.

de Jonge MJ, Loos WJ, Gelderblom H, Planting AS, van der Burg ME, Sparreboom A, Brouwer E, van Beurden V, Mantel MA, Doyle E, Hearn S, Ross G, Verweij J. de Jonge MJ, et al. J Clin Oncol. 2000 May;18(10):2104-15. doi: 10.1200/JCO.2000.18.10.2104. J Clin Oncol. 2000. PMID: 10811676 Clinical Trial.

6

Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens.

Loos WJ, Gelderblom H, Sparreboom A, Verweij J, de Jonge MJ. Loos WJ, et al. Clin Cancer Res. 2000 Jul;6(7):2685-9. Clin Cancer Res. 2000. PMID: 10914710

7

Gender-dependent pharmacokinetics of topotecan in adult patients.

Loos WJ, Gelderblom HJ, Verweij J, Brouwer E, de Jonge MJ, Sparreboom A. Loos WJ, et al. Among authors: gelderblom hj. Anticancer Drugs. 2000 Oct;11(9):673-80. doi: 10.1097/00001813-200010000-00001. Anticancer Drugs. 2000. PMID: 11129727 Clinical Trial.

8

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.

Gelderblom H, Verweij J, Nooter K, Sparreboom A. Gelderblom H, et al. Eur J Cancer. 2001 Sep;37(13):1590-8. doi: 10.1016/s0959-8049(01)00171-x. Eur J Cancer. 2001. PMID: 11527683 Review.

9

Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer.

Gelderblom H, Sparreboom A, de Jonge MJ, Loos WJ, Wilms E, Mantel MA, Hennis B, Camlett I, Verweij J, van der Burg ME. Gelderblom H, et al. Br J Cancer. 2001 Oct 19;85(8):1124-9. doi: 10.1054/bjoc.2001.2014. Br J Cancer. 2001. PMID: 11710824 Free PMC article. Clinical Trial.

10

Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies.

Gelderblom H, Loos WJ, Verweij J, van der Burg ME, de Jonge MJ, Brouwer E, Nooter K, Stoter G, Sparreboom A. Gelderblom H, et al. Eur J Cancer. 2002 Jan;38(1):205-13. doi: 10.1016/s0959-8049(01)00348-3. Eur J Cancer. 2002. PMID: 11750851

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

504 results

Search Page

Filters